Clinical Trial Update: Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study [Phase 2]

View source ↗

Summary

Phase 2 translational study evaluating olaparib in recurrent ovarian cancer with BRCA1/2 wild-type, focusing on platinum-sensitive cases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | Phase 2 | Status: UNKNOWN